Other therapeutic opportunities in CDX2-suppressed colorectal cancers arise for the sub-set that are MSI high or have a high TMB, which could be candidates for immunotherapy with immune checkpoint inhibitors, and for the BRAF mutated sub-set, could be treated with BRAF inhibitor combinations with anti-EGFR monoclonal antibodies [4,6]. Here, CDX2 is linked to colorectal cancer.